Stock Market Reviews

RMD (ResMed Inc.) News

Get the latest news, insights, and market updates on RMD (ResMed Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Resmed CEO Mick Farrell on new technologies, tariffs and AI
  The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and tariffs.
  Nov 17, 2025 - $RMD
• Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 21% gain
  ResMed Inc. ( NYSE:RMD ) shareholders might be concerned after seeing the share price drop 15% in the last quarter. On...
  Nov 16, 2025 - $RMD
• Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
  INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placement and regi
  Nov 14, 2025 - $RMD
• 1 S&P 500 Stock to Research Further and 2 We Turn Down
  The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
  Nov 11, 2025 - $RMD
• Top Stock Reports for Exxon Mobil, Home Depot & NextEra Energy
  Exxon Mobil, Home Depot and NextEra Energy headline today's Zacks reports, each revealing key growth drivers and challenges shaping 2025 performance.
  Nov 11, 2025 - $RMD
• 22% Of This ResMed Insider's Holdings Were Sold
  Insiders were net sellers of ResMed Inc.'s ( NYSE:RMD ) stock during the past year. That is, insiders sold more stock...
  Nov 10, 2025 - $RMD
• ResMed’s Q3 Earnings Call: Our Top 5 Analyst Questions
  ResMed’s third quarter results aligned with Wall Street’s revenue expectations, while its non-GAAP earnings per share moderately outpaced consensus. Management attributed the quarter’s performance to robust demand for both devices and masks, particularly in the U.S., Canada, and Latin America, where mask resupply programs and new product launches drove growth. CEO Michael Farrell highlighted the contribution of recent acquisitions and continued investment in digital health, noting, “Our global t
  Nov 6, 2025 - $RMD
• Is Now The Time To Put ResMed (NYSE:RMD) On Your Watchlist?
  Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
  Nov 5, 2025 - $RMD
• ResMed Inc (RMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
  ResMed Inc (RMD) reports a robust quarter with 9% revenue growth, strategic product launches, and expansion in key markets despite facing industry challenges.
  Oct 31, 2025 - $RMD
• RMD Q3 Deep Dive: ResMed Launches New Mask Platform and Invests in U.S. Operations
  Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit of $2.55 per share was 2.1% above analysts’ consensus estimates.
  Oct 31, 2025 - $RMD